Hagerty (HGTY) Q3 2026 Earnings Call Transcript

Hagerty reported 18% written-premium growth and $257 million in adjusted EBITDA for the first nine months of 2026, up 43%, and raised full-year adjusted EBITDA guidance to $305 million-$315 million and net income guidance to $48 million-$60 million. Results benefited from $32 million of lower estimated losses and operating leverage; management cautioned that a $52 million benefit from capitalized acquisition costs is a timing effect that will not repeat in 2027. Third-quarter marketplace revenue fell 6% to $32 million, while management noted collector-car prices could cool after sharp gains.

Analysis

The earnings signal is positive, but the reported acceleration overstates the forward run-rate: a $52 million acquisition-cost capitalization benefit is largely exhausted, while favorable loss development—including a current-year estimate reduction—may not persist. The key underwriting test is whether the combined ratio stays strong on earned experience, not whether this quarter’s reserve estimates hold. If claims normalize, earnings could face a double headwind just as investors reset expectations for 2027.

The more durable upside is distribution and retention: State Farm conversions and the broader agent network can add policies without relying on collector-car appreciation. But conversion timing and seasonality make near-term policy counts noisy. Broad Arrow’s auction growth may feed insurance and membership acquisition, though the revenue decline despite higher auction volume underscores that vehicle mix and inventory sales can obscure underlying activity. A pause in high-end valuations would threaten auction enthusiasm and collateral values before it necessarily impairs the core insurance franchise.

For the next 1–3 months, the catalyst is a credible 2027 bridge separating underlying operating leverage from the disappearing accounting tailwind and favorable loss estimates. Over 6–18 months, policy growth, retention, and claim severity will determine whether the ecosystem investments compound. The contrarian risk is treating strong nine-month EBITDA growth as fully repeatable; the counterpoint is that the business may still grow through distribution even if auction prices cool. Valuation and normalized earnings data are missing, so there is not enough here to justify chasing the shares.

Key Decisions for Investors

• Do not chase HGTY solely on the raised 2026 outlook. Before initiating a long, verify the 2027 guidance bridge and normalize 2026 EBITDA for the $52 million capitalization benefit and favorable loss-estimate changes.
• Put HGTY on a conditional buy-on-weakness watchlist over the next 1–3 months if policy growth and retention remain firm and guidance indicates operating leverage persists after normalization. Reassess if policy additions weaken beyond seasonal/timing effects or claims trends reverse materially.
• Monitor the next call for current-accident-year loss picks, State Farm conversion pace, and Broad Arrow auction economics. A sustained deterioration in underwriting or a sharper-than-expected cooling in high-end sales would falsify the constructive thesis; no price target is supportable without valuation data.